What are the key drivers and resistors for development of diagnostics and therapeutics in orphan diseases? How to build a value proposition and sustainable business plan in this setting? When moving outside R&D, which additional challenges arise? How to design clinical trials and establish strategic partnerships? Which efforts can be undertaken to ensure access and affordability of orphan disease drugs?
Join us in Leuven to get the answer to these questions and an update on breaking innovations in orphan diseases from frontline speakers including:
Francis Arickx | RIZIV Belgium, Kristof Bonnarens | Pharma-be, Hans Büller | Fair Medicine, Paul Coppo | AP-HP Paris, Hilde De Winter | Ablynx, Daan Dierickx | UZ Leuven, Carla Hollak | AMC Amsterdam, Vinciane Knappenberg | RIZIV Belgium, Diane Kleinermans | Belgian Ministry of Social Affairs and Health, Luc Kupers | Sanofi, Kristina Larsson | EMA, Ingrid Maes | Inovigate, Ana Palma | Sobi, Hanspeter Rottensteiner| Shire, Huub Schellekens | Universiteit Utrecht, Steven Simoens | KU Leuven, Walter Van Dyck | Vlerick Business School, Frank Vanderdonck | Avivia, Agnès Veyradier | AP-HP Paris, Flora Peyvandi | University of Milan, Dirk Vander Mijnsbrugge | Pfizer and many more.
Target audience: junior & senior researchers, MD's, pharmaceutical industry and policy makers.
Please visit our website for more details or consult the program book.
The PROFILE project is funded by the H2020 programme of the European Union.
Date:
Location:
Provinciehuis Vlaams-Brabant. Leuven, Belgium
Price:
To register, please click here. Early bird registration until 30 June 2017.
flanders.bio members are entitled to a 15% reduction on the registration fee. Contact us to obtain your unique registration code.
Language:
English
Organiser(s):
KU Leuven / PROFILE
